Evidence map›Paper›PMID 35251315›Full record

ArticleTherapeutic advances in medical oncology2022

First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.

Sonja Levy, Wieke H M Verbeek, Ferry A L M Eskens, José G van den Berg, Derk Jan A de Groot, Monique E van Leerdam, Margot E T Tesselaar

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02695459 (Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02695459 phase2unknown statusnot on this map

Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin

TypeinterventionalSponsorThe Netherlands Cancer InstituteRan2016 to 2021Enrolled39ConditionsNeuroendocrine CarcinomasArmscisplatinum and everolimus
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sonja LevyDepartment of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Wieke H M VerbeekDepartment of Gastroenterological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ferry A L M EskensDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
José G van den BergDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Derk Jan A de GrootDepartment of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Monique E van LeerdamDepartment of Gastroenterological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Margot E T TesselaarDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
The Netherlands Cancer Institute · NLErasmus MC Cancer Institute · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtrapulmonary neuroendocrine carcinoma (EP-NEC) are an aggressive subgroup of neuroendocrine neoplasms (NEN). Advanced EP-NEC is generally treated with platinum-based cytotoxic regimens, but progressive disease occurs rapidly, resulting in a poor prognosis. Genetic alterations in the mammalian target for rapamycin (mTOR) pathway have been identified in NEN, providing a rationale for treatment with the mTOR-inhibitor everolimus.

methodsA prospective phase 2 single-arm study included patients with advanced EP-NEC from three Dutch NEN expertise centres between March 2016 and January 2020. Treatment consisted of cisplatin 75 mg/m

resultsThirty-nine patients, with a median age of 64 years (range: 28-74), of whom 20 (51%) were male, were enrolled. DCR was 82.1% (95% confidence interval (CI): 66.4-92.4), with an ORR of 58.9% (CI: 42.1-74.4). Median duration of response was 6.4 (CI: 5.8-7.0) months and median progression-free survival was 6.0 (CI: 4.3-7.8) months. Three patients (8%) had durable responses lasting  > 12 months. Median overall survival was 8.7 (CI: 7.8-9.6) months. Most common grade 3/4 toxicities were haematological (36%) and renal (21%).

conclusionEverolimus in combination with cisplatin is an effective first-line treatment option for advanced EP-NEC, especially in highly selected patients.

trial registrationClinicaltrials.gov, NCT02695459, https://clinicaltrials.gov/ct2/show/NCT02695459.

Indexed as

cisplatineverolimusneuroendocrine carcinoma

Identifiers

PMID35251315
PMCPMC8891910
OpenAlexW4214581937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.